Depression and Traumatic Brain Injury
|ClinicalTrials.gov Identifier: NCT00254007|
Recruitment Status : Completed
First Posted : November 15, 2005
Last Update Posted : April 28, 2017
Problem: Depressive symptoms are a common mental health problem following traumatic brain injury (TBI), occurring in up to 87% of patients. Depression following TBI has important consequences including poor functioning, lack of ability to return to work and family activities and prolonged TBI symptoms. The reason depression develops in some patients following TBI is unknown, making treatment difficult.
One type of brain protein that shows genetic differences between people is called the serotonin transporter. People can be divided by whether or not they have a short protein (S allele) or a long protein (L allele) which influences the amount of serotonin transporter. Serotonin is a key brain chemical in depression in many mental/psychiatric illnesses. We think that the genetic differences in the serotonin transporter, that may not make a difference before TBI, may become important after TBI due to the nature of these injuries.
Methods: A consecutive sample of 200 patients attending a TBI clinic who have sustained a mild-to-moderate TBI (American Congress of Rehabilitation Medicine criteria) within the last 2 months will be assessed for the presence of major depression (standard criteria, standardized interview). In phase I, blood samples from patients with mild-to-moderate TBI with depression and without depression will be checked for the presence of the 5-HTTPR genetic difference. This will allow us to study if the S allele is more likely in TBI patients with depression. In phase II, the patients with depression will be treated with the SSRI citalopram for 6 weeks. At 6 weeks, or upon discontinuation of citalopram, depression will be assessed again. This will allow us to study if depressed patients with the S allele respond more poorly to treatment. Persons assessing depression after treatment will not know the genetic makeup of each patient.
Results Expected: If the serotonin transporter genetic difference confers susceptibility to depression following TBI, this will provide important information on what causes depression following TBI and document a risk factor for depression previously unstudied in this population. Also, as SSRI antidepressants are used to treat depression in TBI, this study may identify a subgroup of TBI patients in whom different medications should be given or additional medications are required.
|Condition or disease||Intervention/treatment||Phase|
|Depression Traumatic Brain Injury||Drug: citalopram (celexa)||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Serotonin Transporter Gene Polymorphism and Major Depression Following Traumatic Brain Injury|
|Study Start Date :||July 2003|
|Actual Primary Completion Date :||December 2005|
|Actual Study Completion Date :||May 2010|
Drug: citalopram (celexa)
- - Hamilton Depression Rating Scale (HAM-D) [ Time Frame: Baseline, 6 weeks and 10 weeks (if applicable) ]
- Beck Depression Inventory (BDI), Rivermead Head Injury Follow-up Questionnaire (RHFQ), General Health Questionnaire (GHQ), Rivermead Post Concussion Disorder Questionnaire (RPDQ) [ Time Frame: Baseline, 6 weeks and 10 weeks (if applicable) ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00254007
|Sunnybrook Health Sciences Centre|
|Toronto, Ontario, Canada, M4N 3M5|
|Principal Investigator:||Krista L Lanctot, PhD||Sunnybrook Health Sciences Centre|